Fluphenazine Decanoate

Summary

Fluphenazine Decanoate (CHEMBL1200854) is an approved small-molecule phenothiazine antipsychotic drug; indicated across 1 condition including psoriasis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 28
• Chemistry: 591.8 Da · C32H44F3N3O2S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200854
Name	Fluphenazine Decanoate
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	3388
ChEBI	CHEBI:5124
Molecular formula	C32H44F3N3O2S
Molecular weight	591.8
InChIKey	VIQCGTZFEYDQMR-UHFFFAOYSA-N

SMILES: CCCCCCCCCC(=O)OCCN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F

IUPAC name: 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethyl decanoate

ChEBI definition: The prodrug of fluphenazine, an antipsychotic drug used for the symptomatic management of psychosis in patients with schizophrenia.

Pharmacological roles (ChEBI): phenothiazine antipsychotic drug, prodrug, dopaminergic antagonist.

Also known as: Dapotum d, Decazate, Depot, Fluphenazine decanoate, Fluphenazini decanoas, Lyogen, Modecate, Modecate conc, Moditen depot, NSC-169510, Prolixin decanoate, QD-10733

Patent coverage: 1,115 distinct patent families (4,373 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 4,349 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
psoriasis	2	MONDO:0005083	EFO:0000676

Clinical trials

Total trials: 28.

Phase distribution

Phase	Trials
PHASE2	9
PHASE4	6
PHASE3	4
Not specified	4
PHASE2/PHASE3	2
PHASE1/PHASE2	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02283996	PHASE4	RECRUITING	Adhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment
NCT06778213	PHASE4	RECRUITING	Evaluation of the Efficacy of Allergen-specific Immunotherapy Using Assessment in an Allergen Exposure chamber-a Randomized Placebo-controlled Double-blind Study
NCT00014001	PHASE4	COMPLETED	CATIE- Schizophrenia Trial
NCT01155869	PHASE4	TERMINATED	Pilot Study of Depot NTX in Homeless Veterans
NCT01371526	PHASE4	COMPLETED	Revival of Stem Cells in Addison’s Study
NCT02146547	PHASE4	COMPLETED	European Long-acting Antipsychotics in Schizophrenia Trial
NCT00123669	PHASE2/PHASE3	COMPLETED	Primary Progesterone Therapy for Operable Breast Cancer
NCT00577408	PHASE3	COMPLETED	Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone
NCT00705783	PHASE3	COMPLETED	Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
NCT00706654	PHASE3	COMPLETED	Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
NCT00781898	PHASE2/PHASE3	COMPLETED	Treatment Study Using Depot Naltrexone (1/6) Philadelphia Coord/Data Mgmt Site
NCT01415960	PHASE3	COMPLETED	Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
NCT07185815	PHASE1/PHASE2	RECRUITING	Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine
NCT00113360	PHASE2	COMPLETED	RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma
NCT00332228	PHASE2	COMPLETED	Behavioral Naltrexone Therapy: A Novel Treatment for Heroin Dependence
NCT00356200	PHASE2	TERMINATED	Fluphenazine Decanoate for Psoriasis
NCT00363051	PHASE2	COMPLETED	Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy
NCT00781911	PHASE2	COMPLETED	A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer
NCT01069094	PHASE1/PHASE2	COMPLETED	A Study of Progenta (CDB-4124) in Pre-menopausal Women With Symptomatic Leiomyomata
NCT01564017	PHASE2	COMPLETED	Dose-response Study With Subcutaneous Immunotherapy of an Standardized Dermatophagoides Pteronyssinus (DPT) Extract
NCT01567306	PHASE2	COMPLETED	Phase II Trial With Subcutaneous Immunotherapy in Patients Sensitized to Phleum Pratense
NCT02807363	PHASE2	COMPLETED	A Study of Pharmacokinetic/Pharmacodynamic Profile of Orally Administered Leuprolide in Healthy Female Volunteers
NCT03348527	PHASE2	COMPLETED	A Study to Evaluate the Safety, Tolerability and Efficacy of a Liproca® Depot Injection in Patients With Prostate Cancer
NCT01489020	PHASE1	COMPLETED	Subcutaneous Immunotherapy in Patients Sensitized to Dermatophagoides Pteronyssinus (DPT)
NCT07552506	Not specified	NOT_YET_RECRUITING	Clinical Study on the Preservation of Ovarian Function in Patients With Aplastic Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation Using Goserelin
NCT07583563	Not specified	NOT_YET_RECRUITING	An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly
NCT00756990	Not specified	COMPLETED	Depot Naltrexone Treatment of Opioid Dependent Parolees
NCT02238431	Not specified	WITHDRAWN	Down-regulated Hormonally Controlled Cycles for Vitrification-warmed Blastocyst Transfers

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).